1 In contrast,
there was no difference in 24-hour UFC excretion: 6.91 n
2 In contrast,
there was no difference in 24-month PFS or OS for R2CHOP
3 There was no difference in 3-year overall survival betwe
4 There was no difference in 30 day survival between weeke
5 There was no difference in 5-year breast cancer-specific
6 There was no difference in 90-day survival: 74.3% (156 o
7 closure subjects had longer VLs and ALs, but
there was no difference in ACD.
8 However,
there was no difference in activities of tau kinases and
9 There was no difference in adjusted angiographic quality
10 At 36 months,
there was no difference in adjusted risk of mortality be
11 There was no difference in adverse events.
12 There was no difference in adverse events.
13 There was no difference in age, visual acuity, corticost
14 There was no difference in all-cause hospitalization bet
15 There was no difference in all-cause mortality at 2 year
16 justment for covariates (including surgery),
there was no difference in all-cause mortality between V
17 There was no difference in angiography (hs-report: 11.9%
18 There was no difference in anxiety levels between groups
19 There was no difference in any interval between patients
20 There was no difference in any of the groups in time to
21 ts with SM as compared to those with CM/MIS,
there was no difference in AOPP and AGE concentrations b
22 te markedly different inactivation dynamics,
there was no difference in AP parameters across a wide r
23 In children and adolescents (age 6-17 years)
there was no difference in asthma or sinus symptoms but
24 Among subjects without early RSV-LRI,
there was no difference in asthma risk or peak flow vari
25 There was no difference in atherosclerosis between Zfp14
26 rs in negative cultures, P = .001); however,
there was no difference in bacterial growth between the
27 There was no difference in baseline demographics between
28 There was no difference in BCG-specific T-cell prolifera
29 There was no difference in BDNF levels of filaggrin-posi
30 There was no difference in binding of CHIR to different
31 (189/194 [97.5%]) resulted in a live birth;
there was no difference in birth outcomes according to T
32 There was no difference in biventricular ejection fracti
33 There was no difference in blood pressure at baseline be
34 There was no difference in body condition, antibody resp
35 There was no difference in body weight or insulin secret
36 neal and trigeminal ganglia titers, although
there was no difference in brain titers.
37 At rest
there was no difference in [
Ca(2+) ]i between age groups
38 Among participants with CAC>0,
there was no difference in CAC score (P=0.20), area (P=0
39 There was no difference in cancer prevalence between gro
40 ments (9.6% versus 2.4%; P<0.0001); however,
there was no difference in CHA2DS2-VASc scores (scores >
41 There was no difference in change in FEV1 at 12 months (
42 There was no difference in circuit life whether using bl
43 There was no difference in clinically relevant postopera
44 tal collagen content developed normally, and
there was no difference in COL1A1 gene expression.
45 There was no difference in colon HIS of Mdr1a (-/-) mice
46 Regardless of hospital type,
there was no difference in concordance between IV-only a
47 he generation of virus-specific T cells, and
there was no difference in control of JHMV replication c
48 There was no difference in conversion to AD dementia bet
49 There was no difference in cortical amyloid (measured by
50 than those with chronic VKH (P < .001), but
there was no difference in corticosteroid-sparing contro
51 There was no difference in cytotoxicity observed between
52 ild-type bone marrow-derived mast cells, but
there was no difference in degranulation when cells were
53 There was no difference in delirium incidence between pa
54 There was no difference in delirium prevalence or durati
55 There was no difference in demographic and OCT-derived a
56 There was no difference in demographic or allometric mea
57 Although
there was no difference in DFS between anatomical and no
58 There was no difference in diagnostic accuracy between t
59 There was no difference in discharge Hb levels, morbidit
60 3.0 and 16.7 months, respectively (P = .33);
there was no difference in disease-free survival (P = .4
61 erology by reference laboratory testing, and
there was no difference in distribution of positive sero
62 By using the Medicare Limited 5% dataset,
there was no difference in driving distance between bene
63 There was no difference in duration of ventilation or IC
64 There was no difference in DVT resolution (P = .41).
65 There was no difference in E12 in the right ventricular
66 There was no difference in EAC risk between antireflux s
67 There was no difference in EC density in eyes treated wi
68 There was no difference in ECV between patients without
69 There was no difference in efficacy of antituberculosis
70 There was no difference in either MBL concentrations or
71 Once referred,
there was no difference in elapsed-time to program entry
72 ays per child than in the control group, and
there was no difference in emergency department (ED) vis
73 Similarly,
there was no difference in end-of-study ISI (2.5 vs. 2.7
74 At postoperative days 3 and 30,
there was no difference in estimated glomerular filtrati
75 ency-associated gene, EBNA-2, was performed,
there was no difference in expression between blasting o
76 There was no difference in fat-free mass increment in WF
77 Surprisingly, between P2 and P50
there was no difference in fibroblast proliferation at t
78 forces at low isokinetic velocities, whereas
there was no difference in force at the highest velociti
79 There was no difference in fracture location, degree of
80 By Kaplan-Meier analysis,
there was no difference in freedom from CVA or TIA for t
81 However,
there was no difference in GA content in tissues between
82 For Medicare beneficiaries,
there was no difference in geographic access to YAG lase
83 There was no difference in glucose levels.
84 group compared with in the Unfav-BEP group;
there was no difference in grade 1-2 febrile neutropenia
85 Overall,
there was no difference in graft survival between damage
86 There was no difference in graft survival rate regarding
87 There was no difference in GSRS-IBS scores between glute
88 olling centers (HR 2.22, 95% CI, 1.41-3.49),
there was no difference in HIV and HCV monoinfected pati
89 There was no difference in hospital length of stay, deve
90 There was no difference in hospital stay: 4 days (interq
91 There was no difference in HRQOL.
92 There was no difference in ICU-free days: 18 days (inter
93 (HR, 0.79 [95% CI, 0.69-0.91]; P=0.001), and
there was no difference in in-hospital morbidity.
94 There was no difference in incidence of undetected ACS.
95 e headache group as well as the non-headache
there was no difference in infarct volumes, in the distr
96 ter infection success at 26 degrees C, while
there was no difference in infection between the two str
97 There was no difference in infection rates between studi
98 There was no difference in initial treatment outcomes; h
99 I, .33-1.01; P = .053; I(2) = 92%); however,
there was no difference in injecting risk-taking behavio
100 There was no difference in intensity of risk factor cont
101 reomer pairs entered cells equally well, and
there was no difference in intracellular accumulation of
102 compared with age-matched controls, whereas
there was no difference in length of stay between the co
103 id not differ in size or fibrin content, and
there was no difference in levels of circulating thrombi
104 rols on a Trp53(+/-) genetic background, and
there was no difference in levels of phosphorylated p53
105 with BMDCs treated with free oxLDL, whereas
there was no difference in levels of TNF-alpha or IL-6.
106 There was no difference in liver attenuation between gro
107 There was no difference in long-term or 30-day mortality
108 and 41 months for OR and EVAR, respectively,
there was no difference in long-term survival (5 years 6
109 In adjusted analyses,
there was no difference in long-term survival for right-
110 There was no difference in major adverse cardiac events
111 There was no difference in major or nonmajor clinically
112 There was no difference in mean arterial pressure at 1,
113 There was no difference in mean evaluation score between
114 There was no difference in mean ICH-volume between the t
115 There was no difference in mean tissue PGE2 between the
116 In addition,
there was no difference in mean visual outcome of the fi
117 When isotopes were compared,
there was no difference in measured spatial resolution e
118 There was no difference in median 30-day page views (409
119 There was no difference in median DFS (GemErlo 11.4 mont
120 There was no difference in mitochondrial membrane potent
121 After adjusting for covariates,
there was no difference in mortality (abusive head traum
122 asal cannulae were compared with usual care,
there was no difference in mortality (high-flow nasal ca
123 [OR], 1.37; 95% CI, 1.01-1.86; P = .04) and
there was no difference in mortality among hospitals mee
124 There was no difference in mortality between heparin-ind
125 There was no difference in mortality between the groups
126 Before program launch,
there was no difference in mortality trends between the
127 prevention of S. pneumoniae bacteremia, and
there was no difference in mortality.
128 At baseline,
there was no difference in MR grade, LV dyssynchrony, or
129 ete revascularization was achieved with PCI,
there was no difference in myocardial infarction between
130 There was no difference in myocyte cross-sectional area
131 There was no difference in noncardiovascular or cancer d
132 However,
there was no difference in nonfatal stroke, cardiovascul
133 After adjustment,
there was no difference in NPZ-6 scores between PHIV+/no
134 There was no difference in number of MT, clinical AL, an
135 There was no difference in number of patients showing im
136 There was no difference in organ failure-free days (6 d;
137 lysis, PH reduced overall survival (OS), but
there was no difference in OS and time to recurrence pos
138 There was no difference in OS between patients with or w
139 There was no difference in OS between the two groups.
140 In contrast,
there was no difference in OS for cN- patients based on
141 ncommon, with no differences between groups;
there was no difference in other serious adverse events
142 There was no difference in outcomes 12 months after inju
143 critically ill patients with severe sepsis,
there was no difference in outcomes between beta-lactam
144 6.73 mum; range, 10.31-27.38 mum) (P = .02);
there was no difference in overall choroidal thickness b
145 There was no difference in overall survival (hazard rati
146 as more frequent with WBRT than with SRS and
there was no difference in overall survival between the
147 There was no difference in overall survival for gefitini
148 In EGFR FISH-negative tumors,
there was no difference in overall survival with gefitin
149 However,
there was no difference in oxygenation between groups: S
150 Although
there was no difference in pancreatitis severity in the
151 For transplanted patients (N = 8088),
there was no difference in patient or graft survival bet
152 There was no difference in patient or graft survival.
153 tion and wound infection in the obese group,
there was no difference in patient or graft survival.
154 There was no difference in PCa-specific mortality (P = .
155 At the final analysis,
there was no difference in PFS (hazard ratio [HR] of pla
156 There was no difference in PFS.
157 Although
there was no difference in PGF2alpha levels in PVAT betw
158 There was no difference in physical outcomes, although U
159 Despite this,
there was no difference in plasma concentration of IL-6
160 Similarly,
there was no difference in pooled 30-day stroke post TAV
161 There was no difference in positive and negative results
162 There was no difference in positive culture reports with
163 There was no difference in postoperative delirium betwee
164 There was no difference in postoperative pain scores, op
165 There was no difference in prevalence between those who
166 There was no difference in proportions with microbiologi
167 There was no difference in quality of life between the 2
168 The primary endpoint was not met, since
there was no difference in radiologic response between t
169 In the CEA group,
there was no difference in recurrent cerebrovascular eve
170 There was no difference in remission rates between group
171 There was no difference in renal function or rates of bi
172 Nevertheless,
there was no difference in renal infiltration with ED1 (
173 There was no difference in reperfusion strategy for the
174 There was no difference in responder rate in the PFO clo
175 In univariate analysis,
there was no difference in rim area rate before and afte
176 There was no difference in risk between the four least s
177 p treated with dabigatran 75 mg twice daily,
there was no difference in risk compared with warfarin f
178 There was no difference in risk of adverse events requir
179 Although
there was no difference in risk of graft failure across
180 There was no difference in school grades with 1 exposure
181 There was no difference in secondary outcomes including
182 There was no difference in seizure incidence in patients
183 ith allopurinol (10% versus 2%, P=0.01), but
there was no difference in serious adverse event rates b
184 In contrast,
there was no difference in serum PSA or CRP levels in th
185 4.3% vs 27.5 +/- 17.5%, P = 0.016); however,
there was no difference in sputum neutrophils in obese c
186 There was no difference in SSIs at 4 days postoperativel
187 There was no difference in surgical success (P=0.98).
188 There was no difference in survival at 1 (83.6% [95% CI,
189 There was no difference in survival between motor subtyp
190 With the traditional TNM staging system,
there was no difference in survival between stages (P =
191 There was no difference in survival or in the incidence
192 When the parasitoid was excluded,
there was no difference in survival rate of mealybugs be
193 Moreover,
there was no difference in susceptibility to C. tropical
194 ence interval [CI]: -66, -26, P < .001), but
there was no difference in sustained reading speeds betw
195 There was no difference in syphilis incidence between th
196 6% vs. -4%; IQR, -14 to +4%; P = 0.003), but
there was no difference in TAPSE.
197 There was no difference in temperature sensitivity of th
198 elay between stop and change stimulus, while
there was no difference in the 300 ms delay condition.
199 Additionally,
there was no difference in the ability of mu-opioid rece
200 Among the 767 patients without trauma,
there was no difference in the adjusted odds ratio (aOR)
201 There was no difference in the anti-hyperalgesic and ant
202 There was no difference in the area under the plasma vas
203 ed narrow-band UVB exposure (n = 58) </=6 mo.
There was no difference in the change from baseline LDL-
204 There was no difference in the change in tissue oxygenat
205 There was no difference in the Childhood Asthma Control
206 There was no difference in the colonization rate between
207 In conclusion,
there was no difference in the comparison of AL, ACD and
208 There was no difference in the composite primary outcome
209 There was no difference in the composite primary outcome
210 rom females was greater than from males, but
there was no difference in the contraction by the TXA2 a
211 ntations in frontal and parietal cortex, but
there was no difference in the decoding accuracy of task
212 with erythromycin than with domperidone, but
there was no difference in the diagnostic yield.
213 There was no difference in the extent to which hyperlact
214 There was no difference in the failure-free survival rat
215 VS was higher between 1 and 2 years, whereas
there was no difference in the first year.
216 There was no difference in the frequency of anti-VEGF in
217 There was no difference in the frequency of postoperativ
218 After propensity score adjustment,
there was no difference in the hazard of the primary com
219 There was no difference in the identification rate, nor
220 There was no difference in the in-hospital mortality rat
221 There was no difference in the initial, final, or improv
222 There was no difference in the level of other cytokines.
223 airment vs 3.1% with targeted screening, but
there was no difference in the likelihood of visual acui
224 There was no difference in the mean level of IgM AVA ach
225 There was no difference in the median length of stay bet
226 There was no difference in the modified Seattle heart fa
227 In patients with ulcerative colitis,
there was no difference in the need for colectomy when c
228 ers (HR 1.27, 95% CI 1.08 to 1.49); however,
there was no difference in the need for surgery when com
229 There was no difference in the neuroscore (p = 0.550).
230 There was no difference in the number of activated caspa
231 was significantly larger in WT mice, whereas
there was no difference in the number of alveolar lesion
232 There was no difference in the number of patients reques
233 There was no difference in the number of positive lymph
234 There was no difference in the occurrence of adverse eve
235 There was no difference in the occurrence of sustained I
236 characteristics and preligation morbidities,
there was no difference in the odds of death or NDI (adj
237 There was no difference in the odds of readmission for p
238 There was no difference in the ORA between the eyes with
239 There was no difference in the outcome of death/disabili
240 There was no difference in the outcomes of patients base
241 While
there was no difference in the overall pathology, diseas
242 However, in 2013,
there was no difference in the percentage of patients wh
243 versus IPAH (P for interaction = 0.012), but
there was no difference in the placebo-adjusted effect o
244 There was no difference in the polyfunctional or memory
245 er adjustment for age and educational level,
there was no difference in the postoperative cognitive p
246 There was no difference in the postoperative visual acui
247 There was no difference in the prevalence (P > .23) of d
248 There was no difference in the primary end point or its
249 In a propensity score-matched comparison,
there was no difference in the primary end point within
250 adjusted for differences in patient factors,
there was no difference in the primary end point, death
251 There was no difference in the primary endpoint (22 [9%]
252 There was no difference in the primary endpoint of day 1
253 ottic visualization with video laryngoscopy,
there was no difference in the primary outcome of intuba
254 There was no difference in the primary outcome of lactat
255 There was no difference in the primary safety end point
256 Across cohorts,
there was no difference in the proliferation of reactiva
257 There was no difference in the proportion of children wi
258 acrophages were infected with influenza, and
there was no difference in the proportion of infected ce
259 Also,
there was no difference in the proportion of wild-type 2
260 57 patients) reported rates of any bleeding;
there was no difference in the proportions of patients w
261 There was no difference in the rate of grade 2 or higher
262 There was no difference in the rate of maternal and neon
263 There was no difference in the rate of patient, pancreas
264 Similarly,
there was no difference in the rates between ranibizumab
265 There was no difference in the rates of KPro extrusion (
266 There was no difference in the requirement for epinephri
267 was also greater in Loda than HS93-4118, but
there was no difference in the response of photosyntheti
268 There was no difference in the risk of accidental injury
269 After IPTW,
there was no difference in the risk of hospitalization o
270 There was no difference in the risk of miscarriage assoc
271 There was no difference in the risk of scabies, dermatop
272 There was no difference in the secondary end points of 2
273 There was no difference in the severity of gonadal femin
274 -directed thrombolysis group (P = 0.33), and
there was no difference in the severity of the post-thro
275 There was no difference in the study primary outcome or
276 There was no difference in the time to IRIS events betwe
277 There was no difference in the time used by the child's
278 While
there was no difference in the total amounts of phosphol
279 There was no difference in the TTE ordering volume betwe
280 However,
there was no difference in the variance in heterozygosit
281 There was no difference in time on mechanical ventilatio
282 There was no difference in time to onset of asthma, defi
283 There was no difference in total infarct size or ischemi
284 There was no difference in total inpatient stay (d) betw
285 However,
there was no difference in total Treg expansion between
286 There was no difference in toxicities between the 2 grou
287 g (n = 70) and not receiving OST (n = 1882),
there was no difference in treatment completion (97% vs
288 There was no difference in treatment completion, >/=80%
289 Although
there was no difference in treatment success, more patie
290 ses that were performed using radial access,
there was no difference in treatment times between radia
291 Although
there was no difference in trend in nausea scores over t
292 able rhythms (from 58.9% to 69.2%; P<0.001),
there was no difference in unadjusted rate of successful
293 There was no difference in urinary neutrophil gelatinase
294 There was no difference in visual acuity, although more
295 There was no difference in volume size in the pallidum (
296 There was no difference in weight change between the 2 g
297 There was no difference in weight or gestational age at
298 Although
there was no difference in weight-for-age Z score for da
299 There was no difference in willingness to take PrEP betw
300 Likewise,
there was no difference in wound complication rate betwe